Related references
Note: Only part of the references are listed.Bone Marrow Versus Mobilized Peripheral Blood Stem Cells in Haploidentical Transplants Using Posttransplantation Cyclophosphamide
Annalisa Ruggeri et al.
CANCER (2018)
T-Cell-Depleted Haploidentical Stem Cell Transplantation Results Improve With Time in Adults With Acute Leukemia: A Study From the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT)
Simona Sestili et al.
CANCER (2018)
Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience
Hassan A. Aljasem et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Active acute leukaemia: should transplant be offered to all patients?
Batia Avni et al.
HEMATOLOGICAL ONCOLOGY (2017)
Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation
J. Kanda et al.
LEUKEMIA (2017)
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
S. K. Metzelder et al.
EUROPEAN JOURNAL OF CANCER (2017)
Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Bin Gu et al.
LEUKEMIA RESEARCH (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation
Sebastian P. Haen et al.
ANNALS OF HEMATOLOGY (2017)
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
Joan How et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes
R. Vrhovac et al.
BONE MARROW TRANSPLANTATION (2016)
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Espanol de Trasplante Hematopoyetico
Guillermo Orti et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
T. Ruutu et al.
BONE MARROW TRANSPLANTATION (2015)
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥ 10 years
G. Andreola et al.
BONE MARROW TRANSPLANTATION (2015)
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant
Sarah L. Sammons et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients
Nobuhiro Hiramoto et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic. Stem Cell Transplantation
Gita Thanarajasingam et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
Maximilian Christopeit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia
Raynier Devillier et al.
LEUKEMIA & LYMPHOMA (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2012)
Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Claire Roddie et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
David L. Porter et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
A. Czibere et al.
BONE MARROW TRANSPLANTATION (2010)
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
Albert Oriol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
B. E. Shaw et al.
BONE MARROW TRANSPLANTATION (2008)
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation
D. A. Pollyea et al.
BONE MARROW TRANSPLANTATION (2007)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation
Marco Mielcarek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Competing risk analysis using R: an easy guide for clinicians
L. Scrucca et al.
BONE MARROW TRANSPLANTATION (2007)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
B Wassmann et al.
BLOOD (2005)
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
M Eapen et al.
BONE MARROW TRANSPLANTATION (2004)
Chronic graft-versus-host disease
SJ Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation
A Bosi et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
